Dibenzofurane and dibenzothiophene derivatives

文档序号:1509839 发布日期:2020-02-07 浏览:25次 中文

阅读说明:本技术 二苯并呋喃和二苯并噻吩的衍生物 (Dibenzofurane and dibenzothiophene derivatives ) 是由 L·列特扎 A·格特兹 H·赫施曼 M·恩格尔 于 2018-06-11 设计创作,主要内容包括:本发明涉及式I化合物<Image he="140" wi="700" file="DDA0002316000520000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>其制备,其作为液晶介质中的组分的用途以及包含本发明的液晶介质的电光显示元件,其中出现的基团和参数具有权利要求1的定义。(The invention relates to compounds of formula I Their preparation, their use as components in liquid-crystalline media and also electro-optical display elements comprising the liquid-crystalline media according to the invention, where the radicals and parameters which occur have the meanings given in claim 1.)

1. A compound of formula I

Figure FDA0002316000500000011

Wherein

W is-O-or-S-,

Y1and Y2Independently of one another, H, F, Cl, CN or CF3

R11And R12Independently H, unsubstituted with up to 15 carbon atoms, by CN or CF3Alkyl or alkenyl which are monosubstituted or at least monosubstituted by halogen, where one or more CH groups in these radicals2Radical (I)Or may be interrupted by-O-, -S-, -C.ident.C-, -CF in such a way that the oxygen atoms are not linked directly to one another2O-,-OCF2-, -OC-O-or-O-CO-substitution,

R2is unsubstituted with up to 15 carbon atoms, is substituted by CN or CF3Alkyl or alkenyl which are monosubstituted or at least monosubstituted by halogen, where one or more CH groups in these radicals2The radicals may also be interrupted by-O-, -S-, -C.ident.C-, -CF in such a way that the oxygen atoms are not linked directly to one another2O-,-OCF2-, -OC-O-or-O-CO-substitution, and H, halogen, CN, SCN or SF5

A1Is 1, 3-cyclopentylene which may be monounsaturated and may be mono-or polysubstituted by L radicals,

B1in each case the same or different, and is

a)1, 4-phenylene in which one or two CH groups may be replaced by N,

b)1, 4-cyclohexenylene or 1, 4-cyclohexylene, in which one or two non-adjacent CH' s2The radicals being optionally replaced by-O-or-S-, cyclobutane-1, 3-diyl,

c)1, 4-bicyclo [2,2,2] -octylene, spiro [3.3] heptane-2, 6-diyl, naphthalene-2, 6-diyl, decahydronaphthalene-2, 6-diyl, 1,2,3, 4-tetrahydronaphthalene-2, 6-diyl, thiophene-2, 5-diyl,

wherein the radicals a), b) and c) may be mono-or polysubstituted by L radicals,

l is independently in each case F, Cl, CN, SCN, SF5Or straight-chain or branched, in each case optionally fluorinated, alkyl, alkoxy, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy or alkoxycarbonyloxy having 1 to 12 carbon atoms,

Z1and Z2Each independently a single bond, -CF2O-,-OCF2-,-CF2S-,-SCF2-,-CH2CH2-,-CF2CF2-,-CF2CH2-,-CH2CF2-,-CHF-CHF-,-C(O)O-,-OC(O)-,-CH2O-,-OCH2-,-CH2S-,-SCH2-,-CF-CH-, -CH-CF-, -CF-, -CH-or-C.ident.C-,

n is 0, 1 or 2.

2. Compounds of formula I according to claim 1, characterized in that B1Selected from the group consisting of cyclic elements of the formula

Figure FDA0002316000500000021

3. Compounds of formula I according to claims 1 or 2, characterized in that W is-S-.

4. Compound of formula I according to one or more of claims 1 to 3, characterized in that Y is1And Y2At least one of the groups is not H.

5. Compound of formula I according to one or more of claims 1 to 4, characterized in that Y is1And Y2Are all F.

6. A compound of formula I according to claim 1, characterized in that the compound is selected from the group consisting of compounds of formulae I-1 and I-2

Figure FDA0002316000500000031

Wherein the radicals mentioned have the meanings given in claim 1.

7. Compound according to one or more of claims 1 to 6, characterised in that the radicals

Figure FDA0002316000500000032

8. Compound according to one or more of claims 1 to 7, characterized in that

R2Is methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or n-heptyl.

9. Compound according to one or more of claims 1 to 7, characterized in that

R2Is methoxy, ethoxy, n-propoxy, n-butoxy, n-pentoxy, n-hexoxy or n-heptoxy.

10. Compound according to one or more of claims 1 to 7,

R2is F, Cl, CN, SCN, SF5,CF2H,CF3,OCF2H,OCF3or-OCH ═ CF2

11. A compound of formula II

Figure FDA0002316000500000041

Wherein R is11,R12,Y1,Y2,W,Z2,B1,R2And n has the definitions given for formula I in claim 1.

12. Process for the preparation of a compound of formula I according to claim 1, characterized in that a compound of formula II according to claim 11 is converted into a compound of formula I by removing water.

13. Use of a compound according to one or more of claims 1 to 10 in a liquid-crystalline medium.

14. Liquid-crystalline medium, characterized in that it comprises one or more compounds according to one or more of claims 1 to 10.

15. Electro-optical display element, characterized in that it comprises a liquid-crystalline medium according to claim 14.

The prior art discloses VA materials derived from dibenzofurans or dibenzothiophenes.

WO 02/055463 discloses compounds of the formula

Figure BDA0002316000510000021

Wherein X may be O or S, especially Y may be F, R1And R2May be alkyl or alkoxy, and the other parameters have the definitions specified therein. The compounds described therein have negative dielectric anisotropy, but have been developed for ferroelectric LC mixtures and the dielectric anisotropy values of the individual substances have not been described.

WO 2009/091884 generally discloses compounds containing five-membered carbocyclic rings, including compounds of the formula:

wherein X1And X2Is H or F, R is alkyl, R' is alkyl or alkoxy. However, no specific examples of this substance class are described.

One problem solved by the present invention is to provide compounds for liquid-crystalline media having advantageous properties. They should preferably have a negative dielectric anisotropy, which makes them particularly suitable for use in liquid-crystalline media for VA or FFS displays. Regardless of the dielectric anisotropy corresponding to the display type, a compound having an advantageous combination of application-related parameters is required. Among these parameters which must be optimized simultaneously, particular mention should be made of high bright spots over the application time, low rotational viscosity and suitable optical anisotropy, as well as the characteristics for obtaining mixtures with the desired liquid-crystalline phase over a wide temperature range (low melting point, good miscibility with other liquid-crystalline components of the desired type and good solubility and high polarity).

The invention relates to compounds of formula I

Figure BDA0002316000510000032

Wherein

W is-O-or-S-,

Y1and Y2Independently is H, F, Cl, CN or CF3

R11And R12Independently H, unsubstituted with up to 15 carbon atoms, by CN or CF3Alkyl or alkenyl which are monosubstituted or at least monosubstituted by halogen, where one or more CH groups in these radicals2The radicals may also be interrupted by-O-, -S-, -C.ident.C-, -CF in such a way that the oxygen atoms are not linked directly to one another2O-,-OCF2-, -OC-O-or-O-CO-substitution,

R2is unsubstituted with up to 15 carbon atoms, is substituted by CN or CF3Alkyl or alkenyl which are monosubstituted or at least monosubstituted by halogen, where one or more CH groups in these radicals2The radicals may also be interrupted by-O-, -S-, -C.ident.C-, -CF in such a way that the oxygen atoms are not linked directly to one another2O-,-OCF2-, -OC-O-or-O-CO-substitution, and H, halogen, CN, SCN or SF5

A11, 3-cyclopentylene which may be monounsaturated and may be mono-or polysubstituted by L radicals,

B1in each case the same or different, and is

a)1, 4-phenylene in which one or two CH groups may be replaced by N,

b)1, 4-cyclohexenylene or 1, 4-cyclohexylene, in which one or two non-adjacent CH' s2The radicals being optionally replaced by-O-or-S-, cyclobutane-1, 3-diyl,

c)1, 4-bicyclo [2,2,2] -octylene, spiro [3.3] heptane-2, 6-diyl, naphthalene-2, 6-diyl, decahydronaphthalene-2, 6-diyl, 1,2,3, 4-tetrahydronaphthalene-2, 6-diyl, thiophene-2, 5-diyl,

wherein the radicals a), b) and c) may be mono-or polysubstituted by L radicals,

l is independently in each case F, Cl, CN, SCN, SF5Or straight-chain or branched, in each case optionally fluorinated, alkyl, alkoxy, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy or alkoxycarbonyloxy having 1 to 12 carbon atoms,

Z1and Z2Each independently a single bond, -CF2O-,-OCF2-,-CF2S-,-SCF2-,-CH2CH2-,-CF2CF2-,-CF2CH2-,-CH2CF2-,-CHF-CHF-,-C(O)O-,-OC(O)-,-CH2O-,-OCH2-,-CH2S-,-SCH2-, -CF-CH-, -CH-CF-, -CF-, -CH-or-C.ident.C-,

n is 0, 1 or 2.

These compounds have a pronounced negative dielectric anisotropy (. DELTA.. di-elect cons.), and are therefore particularly suitable for use in liquid-crystal mixtures for VA-TFT displays or IPS or FFS displays. As large a negativity as possible Δ ∈ may be advantageous for applications. The compounds of the present invention preferably have a dielectric anisotropy Δ ∈ -4 or less, preferably-6 or less, and most preferably-8 or less. They exhibit good miscibility with conventional substances in liquid-crystal mixtures for displays, which means that they have good solubility in them. The rotational viscosity of the compound and the resulting liquid-crystal mixture is advantageously small and at the same time the respective clearing point is advantageously high.

Other physical, physicochemical and electrooptical parameters of the compounds of the invention are also advantageous for their use in liquid-crystalline media. Liquid-crystalline media comprising these compounds have, in particular, a sufficient nematic phase width, and also good low-temperature and long-term stability, and a sufficiently high clearing point. The low melting point of the compounds of the invention indicates advantageous mixing characteristics. In addition, the compounds of the formula I according to the invention, in particular for VA-TFT displays or displays of the IPS or FFS type, have suitable values for the optical anisotropy Δ n. Preferably, the compounds of the invention have a Δ n greater than 0.15 and less than 0.25. Furthermore, the compounds are relatively easy to prepare. The balanced combination of these advantageous properties greatly increases the mixture composition available for mixtures having negative dielectric anisotropy.

If R in formula I11,R12And R2Each independently an alkyl group, they are straight or branched. Preferably, each of these groups is straight-chain and, unless otherwise specified, has 1,2,3,4, 5, 6 or 7 carbon atoms, andand are therefore preferably methyl, ethyl, propyl, butyl, pentyl, hexyl or heptyl.

If R in formula I11,R12And R2Each independently an alkoxy group, they are linear or branched. Preferably, each of these groups is straight-chain and, unless otherwise specified, has 1,2,3,4, 5, 6 or 7 carbon atoms and is therefore preferably methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy or heptoxy.

R in formula I11,R12And R2And may each independently be a straight-chain or branched alkenyl group having 2 to 15 carbon atoms and having at least one C — C double bond. It is preferably straight-chain and has 2 to 7 carbon atoms. Thus, it is preferably vinyl, prop-1-enyl or prop-2-enyl, but-1-, 2-or but-3-enyl, pent-1-, 2-, 3-or pent-4-enyl, hex-1-, 2-, 3-, 4-or hex-5-enyl, hept-1-, 2-, 3-, 4-, 5-or hept-6-enyl. If two carbon atoms of a C-C double bond are substituted, the alkenyl group may be in the form of E and/or Z isomers (trans/cis). Generally, the respective E isomers are preferred. Among the alkenyl groups, particular preference is given to prop-2-enyl, but-2-enyl or but-3-enyl and pent-3-enyl or pent-4-enyl.

R in formula I11,R12And R2And may also independently be an alkynyl group having 2 to 15 carbon atoms, which is straight or branched chain and has at least one C-C triple bond. Preference is given to 1-or 2-propynyl and 1-, 2-or 3-butynyl.

If R is2Is a polar group, then it is selected from halogen, CN, SCN, SF5Mono-, di-or polyfluoroalkyl having up to 15 carbon atoms, alkenyl, alkoxy or alkenyloxy, preferably F, Cl, CN, SCN, SF5,CF2H,CF3,OCF2H,OCF3or-OCH ═ CF2

Z1The radical is preferably a single bond, -CH2O-,-OCH2-,-CF2O-or-OCF2More preferably, it is a single bond.

Z2The radical is preferably a single bond, -CH2O-,-OCH2-,-CF2O-or-OCF2More preferably, it is a single bond.

Preferably, the ring element B1A cyclic element selected from the group consisting of:

Figure BDA0002316000510000061

more preferably

Figure BDA0002316000510000062

Most preferably

Figure BDA0002316000510000071

Preferably, A1A cyclic element selected from the group consisting of:

Figure BDA0002316000510000072

more preferably

Figure BDA0002316000510000073

Most preferably

Figure BDA0002316000510000074

In these formulae, R11And R12Independently of one another, H or alkyl having 1 to 7 carbon atoms are preferred.

More preferably, R11And R12At least one of the groups is H.

In a very particularly preferred embodiment, R11And R12Are all H.

In a preferred embodiment of the invention, W is-S-.

In the context of the present invention, halogen is fluorine, chlorine, bromine and iodine, especially fluorine and chlorine.

The L group is preferably F, Cl, -CF3Or an alkyl or alkoxy group having 1,2 or 3 carbon atoms.

Preferably, Y in formula I1And Y2At least one of the groups is not H.

More preferably, Y in formula I1And Y2Are all F.

Preferably, n is 0 or 1, more preferably 0.

The compound of formula I is preferably selected from the group consisting of compounds of formulae I-1 and I-2.

Wherein R is11,R12And R2With the definitions given above.

Very particular preference is given to compounds of the formula I-2.

The compounds of formulae I-1 and I-2 are preferably selected from compounds of the following sub-formulae:

Figure BDA0002316000510000082

Figure BDA0002316000510000091

wherein R is2With the definitions given above.

In a first preferred embodiment, R in the formulae I-1a, I-1b, I-2a and I-2b2Is methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl or n-heptyl.

In a second preferred embodiment, R in formulae I-1a, I-1b, I-2a and I-2b2Is methoxy, ethoxy, n-propoxy, n-butoxy, n-pentoxy, n-hexoxy or n-heptoxy.

In a third preferred embodiment, R in formulae I-1a, I-1b, I-2a and I-2b2Is F, Cl, CN, SCN, SF5,CF2H,CF3,OCF2H,OCF3or-OCH ═ CF2Or more preferably F, CF3Or OCF3

If the radicals or substituents in the compounds of the invention or the compounds of the invention themselves are in the form of optically active or stereoisomeric radicals, substituents or compounds, since they have, for example, asymmetric centers, these are also included in the invention. It is apparent here that the compounds of the general formula I according to the invention can be in isomerically pure form, for example in the form of the pure enantiomers, diastereomers, E or Z isomers, trans or cis isomers, or in the form of mixtures of various isomers in any ratio, for example racemates, E/Z isomer mixtures or cis/trans isomer mixtures.

1, 4-substituted cyclohexyl rings of the formula

or-Cyc-

Preferably in the trans configuration, which means that both substituents are in the equatorial position in the thermodynamically preferred chair conformation.

The compounds of the formula I can be prepared by Methods known per se, as described in the literature (for example in standard works, such as Houben-Weyl, Methoden der organischen Chemistry [ Methods of Organic Chemistry ], Georg-Thieme-Verlag, Stuttgart), under reaction conditions which are known and suitable for the abovementioned reactions. Variants which are known per se but are not mentioned here in detail can be used here.

The starting materials may optionally also be formed in situ so that they are not isolated from the reaction mixture but are immediately converted further into the compounds of the formula I.

The synthesis of the compounds of general formula I according to the invention is described by way of example in the examples. The starting materials are available by commonly available literature methods or commercially.

A particularly preferred synthetic route is shown in scheme 1:

scheme 1.

Suitable precursors (1) are described in WO 02/055463 and DE 102015002298 a1 (for W ═ O, R2Alkyl, alkoxy) in EP 2937342a1 (for W ═ S, R)2Alkyl, alkoxy) and in EP 3085753 a1 (for W ═ O, S, R)2=F,Cl,CN,SCN,SF5,CF2H,CF3,OCF2H,OCF3or-OCH ═ CF2). After ortho-metallation, compound 1 is added to the correspondingly substituted cyclopentanone derivative to give the alcohol 2, after which water is removed to give the product 3 according to the invention, which, if appropriate, can be converted further by catalytic hydrogenation into the compound 4 according to the invention. Preferred conditions for metallation are reaction with an alkyl lithium such as n-BuLi in THF at about-70 deg.C, followed by addition of the ketone.

Cyclopentanone and alkyl-and dialkylcyclopentanone derivatives are commercially available and known in the literature or can be prepared in racemic or optically active form in a manner analogous to the synthesis known in the literature. According to the invention, preference is given to using alkyl-substituted cyclopentanones as racemates.

Examples of preferred cyclopentanone derivatives are:

Figure BDA0002316000510000111

the invention further provides compounds of formula II

Figure BDA0002316000510000112

Wherein R is11,R12,Y1,Y2,W,Z2,B1,R2And n has the definitions given for formula I.

The compounds of formula II are prepared by the synthetic methods specified in scheme 1 and working examples and can be converted to compounds of formula I by removing water.

Methods for removing water from alcohols are known to those skilled in the art and are described in Houben-Weyl, Methoden der organischen Chemie, Georg-Thieme-Verlag, Stuttgart.

The processing of the reaction mixture and the subsequent work-up can in principle be carried out in batch reaction or continuous reaction mode. Continuous reaction modes include, for example, reactions in continuous stirred tank reactors, stirred tank cascades, loop or cross-flow reactors, flow tubes or microreactors. The reaction mixture is treated as needed by any one of the following methods: by solid phase filtration, chromatography, separation between immiscible phases (e.g. extraction), adsorption on a solid support, distillation to remove solvents and/or azeotropic mixtures, selective distillation, sublimation, crystallization, co-crystallization or nanofiltration on a membrane.

As already mentioned, the compounds of the formula I can be used in liquid-crystalline media. The present invention therefore also provides a liquid-crystalline medium comprising at least two liquid-crystalline compounds, including at least one compound of the general formula I.

The present invention also provides liquid-crystalline media which comprise one or more compounds of the formula I according to the invention and from 2 to 40, preferably from 4 to 30, components as further constituents. More preferably, these media comprise one or more compounds of the invention and 7 to 25 components. These further components are preferably selected from nematic or nematic (unidirectional or isotropic) substances, in particular from the following classes: azoxybenzene, benzylidene aniline, biphenyl, terphenyl, 1, 3-bis

Figure BDA0002316000510000121

Alkanes, 2, 5-tetrahydropyrans, benzoates of phenyl or cyclohexyl, carboxylates of phenyl or cyclohexylcyclohexane, phenyl or cyclohexyl esters of cyclohexylbenzoic acid, phenyl or cyclohexyl esters of cyclohexylcyclohexanecarboxylic acid, cyclohexylphenyl esters of benzoic acid, of cyclohexanecarboxylic acid or of cyclohexylcyclohexanecarboxylic acid, phenylcyclohexane, cyclohexylbiphenyl, phenylcyclohexylcyclohexane, cyclohexylcyclohexane, cyclohexylcyclohexylcyclohexene, 1, 4-bicyclohexanoic acidPhenyl, 4',4' -dicyclohexylbiphenyl, phenyl-or cyclohexylpyrimidine, phenyl-or cyclohexylpyridine, phenyl-or cyclohexylbis

Figure BDA0002316000510000122

Alkyl, phenyl-or cyclohexyl-1, 3-dithiane, 1, 2-diphenylethane, 1, 2-dicyclohexylethane, 1-phenyl-2-cyclohexylethane, 1-cyclohexyl-2- (4-phenylcyclohexyl) ethane, 1-cyclohexyl-2-biphenylethane, 1-phenyl-2-cyclohexylphenylethane, optionally halogenated

Figure BDA0002316000510000123

Benzyl phenyl ether, tolane and substituted cinnamic acids. The 1, 4-phenylene groups in these compounds may also be monofluorinated or polyfluorinated.

The most important compounds which can be used as further constituents of the media according to the invention can be characterized by the formulae (II), (III), (IV), (V) and (VI):

R'-L-E-R” (II)

R'-L-COO-E-R” (III)

R'-L-OOC-E-R” (IV)

R'-L-CH2CH2-E-R” (V)

R'-L-CF2O-E-R” (VI)

in the formulae (II), (III), (IV), (V) and (VI), L and E may be identical or different and are each, independently of one another, a divalent radical from the group formed by-Phe-, -Cyc-, -Phe-Phe-, -Phe-Cyc-, -Cyc-Cyc-, -Pyr-, -Dio-, -Thp-, -G-Phe-and-G-Cyc-and their mirror images, where Phe is unsubstituted or fluorine-substituted 1, 4-phenylene, Cyc is trans-1, 4-cyclohexylene or 1, 4-cyclohexenylene, Pyr is pyrimidine-2, 5-diyl or pyridine-2, 5-diyl, and Dio is 1, 3-diyl

Figure BDA0002316000510000132

Alk-2, 5-diyl, Thp tetrahydropyran-2, 5-diyl, G2- (trans-1, 4-cyclohexyl) ethyl, pyrimidin-2, 5-diyl, pyridin-2, 5-diyl, 1, 3-diyl

Figure BDA0002316000510000133

Alkane-2, 5-diyl or tetrahydropyran-2, 5-diyl.

Preferably, one of the L and E groups is Cyc or Phe. E is preferably Cyc, Phe or Phe-Cyc. Preferably, the media of the invention comprise one or more components selected from the group consisting of compounds of the formulae (II), (III), (IV), (V) and (VI), wherein L and E are selected from Cyc and Phe, and comprising one or more components selected from the group consisting of compounds of the formulae (II), (III), (IV), (V) and (VI), wherein one of the radicals L and E is selected from the group consisting of Cyc and Phe and the other is selected from the group consisting of-Phe-Phe-, -Phe-Cyc-, -Cyc-Cyc-, -G-Phe-and-G-Cyc-, and optionally one or more components selected from the group consisting of compounds of the formulae (II), (III), (IV), (V) and (VI), wherein the L and E groups are selected from the group consisting of-Phe-Cyc-, -Cyc-Cyc-, -G-Phe-and-G-Cyc-.

R 'and R' in a smaller sub-group of the compounds of the formulae (II), (III), (IV), (V) and (VI) are each independently alkyl, alkenyl, alkoxy, alkoxyalkyl (oxaalkyl), alkenyloxy or alkanoyloxy having up to 8 carbon atoms. This smaller subgroup is referred to hereinafter as group a, and the compounds are designated by sub-formulae (IIa), (IIIa), (IVa), (Va) and (VIa). In most of these compounds, R 'and R' are different from each other, wherein one of these groups is usually alkyl, alkenyl, alkoxy or alkoxyalkyl (oxaalkyl).

In another smaller subgroup, designated group B, of the compounds of the formulae (II), (III), (IV), (V) and (VI), E is

In the group B compounds denoted by the sub-formulae (IIb), (IIIb), (IVb), (Vb) and (VIb), R' and R "have the definitions given for the compounds of the sub-formulae (IIa) to (VIa), preferably alkyl, alkenyl, alkoxy or alkoxyalkyl (oxaalkyl).

In a further smaller sub-group of the compounds of formulae (II), (III), (IV), (V) and (VI), R' is-CN. This subgroup is referred to below as group C and the compounds of this subgroup are described by the sub-formulae (IIc), (IIIc), (IVc), (Vc) and (VIc) respectively. In the compounds of the sub-formulae (IIc), (IIIc), (IVc), (Vc) and (VIc), R' has the definitions given for the compounds of the sub-formulae (IIa) to (VIa) and is preferably alkyl, alkenyl, alkoxy or alkoxyalkyl (oxaalkyl).

In addition to the preferred variants of the radicals A, B and C, further compounds of the formulae (II), (III), (IV), (V) and (VI) having further variants of the substituents envisaged are also generally used. All these substances can be obtained by methods known in the literature or by analogous methods.

The media according to the invention preferably comprise, in addition to the compounds of the general formula I according to the invention, one or more compounds selected from the groups A, B and/or C. In the medium of the invention, the mass ratio of the compounds from these groups is:

group A:

from 0% to 90%, preferably from 20% to 90%, in particular from 30% to 90%.

Group B:

from 0% to 80%, preferably from 10% to 80%, in particular from 10% to 70%.

Group C:

from 0% to 80%, preferably from 5% to 80%, in particular from 5% to 50%.

The medium of the invention preferably comprises from 1% to 40%, more preferably from 5% to 30%, of the compound of formula I according to the invention. The medium preferably comprises one, two, three, four or five compounds of the invention of the formula I.

The media of the invention are produced in a conventional manner per se. In general, the components are preferably dissolved in one another at elevated temperature. The liquid-crystalline phases of the invention can be modified by suitable addition so that they can be used in all types of liquid-crystal display elements known hitherto. Such additions are known to those skilled in the art and are described in detail in the literature (H.Kelker/R.Hatz, Handbook of Liquid Crystals, Verlag Chemie, Weinheim, 1980). For example, pleochroic dyes can be added for producing colored guest-host systems or substances for changing the dielectric anisotropy, the orientation of the nematic phase and/or the viscosity.

Due to their negative Δ ∈, the compounds of the formula I are particularly suitable for VA-TFT displays.

The invention therefore also provides electro-optical display elements comprising the liquid-crystalline media according to the invention. Preferably, the display element is a VA-TFT display element (VA: vertical alignment, TFT: thin film transistor).

Other combinations of embodiments and variants of the invention are apparent from the claims.

Other embodiments of the invention are apparent from the claims and combinations of two or more of these claims.

Hereinafter, the present invention is explained in detail by working examples, but it is not intended to be limited thereto. Those skilled in the art will be able to deduce from the general description details of the procedures in the examples not specifically set forth, generalize them in light of common general knowledge in the art, and apply them to specific problems of interest.

In addition to the customary and well-known abbreviations, the following abbreviations are used:

k: a crystalline phase; n: a nematic phase; sm: a smectic phase;

i: an isotropic phase. The values between these symbols represent the transition temperatures of the substances in question.

Unless otherwise indicated, temperature numbers are in degrees Celsius.

The determination of the physical, physicochemical and electro-optical parameters is carried out by known methods, in particular as described in the manual "Merck Liquid Crystals-

Figure BDA0002316000510000151

-Physical Properties of Liquid Crystals-Description of the Measurements Methods ", 1998, Merck KGaA (Dammstadt).

Hereinbefore and hereinafter, Δ n denotes the optical anisotropy (589nm, 20 ℃ C.) and Δ ε denotes the dielectric anisotropy (1kHz, 20 ℃ C.). The dielectric anisotropy Δ ε was determined at 20 ℃ and 1 kHz. The optical anisotropy Δ n was determined at 20 ℃ and a wavelength of 589.3 nm.

Delta epsilon and Delta n values, extrapolated clearing point (Clp.) and rotational viscosity of the inventive compounds(γ1) Obtained by linear extrapolation from a liquid-crystal mixture consisting of 5 to 10% of the respective compound of the invention and 90 to 95% of a commercially available liquid-crystal mixture ZLI-2857 (for. DELTA. epsilon., Clp.) or ZLI-4792 (for. DELTA.n., gamma.)1) (mixture from MerckkKGaA (Dammstat)).

The following abbreviations represent:

RT Room temperature, about 20 deg.C

m.p. melting Point

MTB methyl tert-butyl ether

THF tetrahydrofuran

EA Ethyl acetate

BuCl n-butyl chloride

TsOH toluene sulfonic acid

BuLi n-butyl lithium

The synthesis of compound 1 is described in DE 102015004271 a 1.

Materials example 1

1.11- (7-ethoxy-4, 6-difluorodibenzothiophen-3-yl) cyclopentanol (3)

Figure BDA0002316000510000161

5.3g (20mmol) of dibenzothiophene 1 are dissolved in 50ml of THF, and a solution of 16.9ml of butyllithium (15%) in hexane (26mmol) is added at-70 ℃. After 1 h at-70 ℃ 2.3g (30mmol) cyclopentanone (2) dissolved in 20 ml THF are added. The cooling was removed and water and MTB ether were added to the mixture at-20 ℃. The aqueous phase was extracted with MTB ether and the combined organic phases were dried over sodium sulfate, filtered and concentrated. The residue was filtered through silica gel (BuCl/EA) and the product fractions were concentrated. The resulting residue (3) (2.5g (81%)) was used in the next step without further purification.

1.23- (cyclopenten-1-yl) -7-ethoxy-4, 6-difluorodibenzothiophene (4)

Figure BDA0002316000510000162

3.5g (10mmol) of alcohol 3 are dissolved in 80ml of toluene, 200mg of p-TsOH are added and the mixture is heated to boiling on a trap. The cooled mixture was filtered through silica gel and rinsed with n-heptane. The residue obtained after concentration of the filtrate was crystallized from ethanol/toluene. This gave 3- (cyclopenten-1-yl) -7-ethoxy-4, 6-difluorodibenzothiophene as colorless crystals at 153 ℃ m.p.

Δε=-8.24

Δn=0.2815

γ1=235mPa s

Example 2: 3- (cyclopentyl) -7-ethoxy-4, 6-difluorodibenzothiophene (4)

Figure BDA0002316000510000171

5.3g (20mmol) of cyclopentene 4 were dissolved in 55ml of THF and hydrogenated to completion over Pd/C. The solution was then filtered and concentrated, and the residue was filtered through silica gel with n-heptane/EA and recrystallized from ethanol and heptane, respectively. 3- (cyclopentyl) -7-ethoxy-4, 6-difluorodibenzothiophene was obtained as colorless crystals at 110 ℃ m.p.

Δε=-8.41

Δn=0.2035

γ1=276mPa s。

16页详细技术资料下载
上一篇:一种医用注射器针头装配设备
下一篇:艾菲康唑的制备及提纯方法

网友询问留言

已有0条留言

还没有人留言评论。精彩留言会获得点赞!

精彩留言,会给你点赞!

技术分类